Literature DB >> 11869827

The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice.

Vladislav Eybl1, Dana Kotyzová, Metodìj Kolek, Jaroslav Koutenský, Peter Nielsen.   

Abstract

The seven week feeding of a diet enriched with 0.5% TMH-ferrocene to male mice was used in this study to produce an iron-overload model in experimental animals for evaluating the effect of deferoxamine (DFO) and deferiprone (L1) on tissue-stored iron, induced lipid peroxidation (LP) and parameters of oxidative status. The iron concentration in the liver reached 600% of the level in control animals. The administration of seven doses of deferoxamine (DFO) i.p. and deferiprone (L1) p.o. (0.72 mmol/kg b.w., every 48 h) during 9th and 10th week significantly decreased the liver, kidneys and heart iron level in both iron-loaded and control mice. The DFO and L1 treatment also equally attenuated lipid peroxidation and increased the GSH level in the liver of iron loaded mice. The glutathione peroxidase (GSH-Px) activity and catalase activity were not affected by iron loading, however, both DFO and L1 caused a decrease of GSH-Px activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11869827     DOI: 10.1016/s0378-4274(01)00541-0

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  6 in total

1.  Post-acute pathological changes in the thalamus and internal capsule in aged mice following controlled cortical impact injury: a magnetic resonance imaging, iron histochemical, and glial immunohistochemical study.

Authors:  Gregory Onyszchuk; Steven M LeVine; William M Brooks; Nancy E J Berman
Journal:  Neurosci Lett       Date:  2009-01-23       Impact factor: 3.046

2.  Effects of iron deprivation or chelation on DNA damage in experimental colitis.

Authors:  M Barollo; R D'Incà; M Scarpa; V Medici; R Cardin; W Fries; I Angriman; G C Sturniolo
Journal:  Int J Colorectal Dis       Date:  2004-04-06       Impact factor: 2.571

Review 3.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 4.  Iron chelation and multiple sclerosis.

Authors:  Kelsey J Weigel; Sharon G Lynch; Steven M LeVine
Journal:  ASN Neuro       Date:  2014-01-30       Impact factor: 4.146

5.  Iron metallodrugs: stability, redox activity and toxicity against Artemia salina.

Authors:  Hector Aguilar Vitorino; Luca Mantovanelli; Flavia Pinheiro Zanotto; Breno Pannia Espósito
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

6.  The role of neutrophil gelatinase-associated lipocalin and iron homeostasis in object recognition impairment in aged sepsis-survivor rats.

Authors:  Yoshikazu Nikaido; Yoko Midorikawa; Tomonori Furukawa; Shuji Shimoyama; Daiki Takekawa; Masato Kitayama; Shinya Ueno; Tetsuya Kushikata; Kazuyoshi Hirota
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.